Clinical trials
3 active studies led by Xenios AG, of 5 in all
Source: ClinicalTrials.gov, Studies with Xenios AG (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Xenios AG or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Xenios AG
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
Trials over time
Studies Xenios AG leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Xenios AG or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Xenios AG: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Xenios AG is in.
From our blog
Stories on the topics Xenios AG works in.
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Ambulance Services: The First Link in Emergency Care
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read